Little is known on the impact of HIV-2 infection on HCV viral replication. The aim of the study was to compare HCV prevalence and viral replication based on HIV types in West Africa.
Introduction
Hepatitis C virus (HCV) infection is a growing public health concern 1,2 in resource limited settings. In Sub-Saharan Africa (SSA), a recent meta-analysis estimated the HCV prevalence at 3.0% (95% CI 2.9-3.1), varying from 6.8% (95% CI 6.0-7.6) in the Central African region to 4.3% (4.0-4.7) in West Africa and 0.9% (0.8-1.0) in Southeast Africa. 3 Chronic HCV infection has been strongly correlated to the development of hepatocellular carcinoma (HCC). 4, 5 Thus, all efforts must be made to prevent and control this disease.
West Africa is also characterized by a high prevalence of HIV and the circulation of both HIV type 1 and 2, which can lead to co-infections with HIV-1 and HIV-2 (HIV-1&2). [6] [7] [8] Due to shared routes of transmission, HCV and HIV co-infection is common and globally 6.0% of HIV-infected people are co-infected in SSA, with some regional differences. 1, 2 Co-infection with HIV adversely affects the course of HCV infection, and co-infected people, particularly those with advanced immunodeficiency have a significantly accelerated progression from liver disease to cirrhosis and hepatocellular carcinoma than HCV mono-infected people. [9] [10] [11] [12] Therefore, HCV screening is very important among HIV-infected patients especially with the availability of new, highly effective anti-viral treatments that can cure HCV. 13, 14 To our knowledge, only one small-scale study from Guinea Bissau has estimated the prevalence of HCV co-infection according to HIV types and did not find any difference between HIV-1 and HIV-2. 15 The objectives of this study were to estimate the prevalence of HCV according to HIV types in the West Africa Database on Antiretroviral Therapy (WADA) HIV-2 cohort in two West African countries and to identify risk factors for HCV positivity.
Materials and Methods
A cross-sectional survey was conducted from March to December 2012 in two countries (Burkina Faso and Côte d'Ivoire) within the WADA HIV-2 cohort. The method of this survey was described in details elsewhere. 16 This cohort is embedded in the International epidemiological Database to Evaluate AIDS (IeDEA) West Africa Collaboration, which is part of the global IeDEA network. 17 All patients aged 18 years and above, registered in the WADA cohort as HIV-2 or dually reactive, who attended one of the participating clinics during the study period and who agreed to participate were included in this survey regardless of ART initiation according to WHO 2010 guidelines. 18 A standardized survey form was used to collect data on patients' demographics, clin-ical and biological characteristics. Two EDTA tubes of blood were collected from each patient and sent to the referral laboratory of the study ( 19 and an in-house ELISA test, developed by the French National Aids and Viral Hepatitis Research Agency (ANRS). 20 The results of this rescreening were previously reported. 21 The aim of this retesting was to perform an accurate HIV type discrimination, since HIV type misclassification has previously been reported in many West African cohorts, especially for HIV-1&2 dually reactive patients. 22 HCV antibodies (anti-HCV) was done using a sequential algorithm with two tests: screening was performed using DIA.PRO The prevalence of HCV was expressed with a 95% confidence interval (95% CI). Groups' comparisons were performed using Student's t test or non-parametric Wilcoxon rank-sum test (non-normal distribution) for continuous variables and using 
Discussion
To our knowledge, this is one of the largest report up to now on HCV co-infection among HIV-positive individuals in West Africa. In this study, the prevalence of HCV infection was high (3.9%; 95% CI 2.7-5.5) based on the positivity of anti-HCV, with statistical difference by country (2.2% in Côte d'Ivoire and 7.8% in Burkina Faso) but not by HIV types.
Our estimate for anti-HCV prevalence is similar to the estimates from a recent meta-analysis conducted among HIV-positive individuals in SSA. In this study, the overall HCV prevalence among the HIVinfected patients from West Africa was 6.7% (95% CI 4.8-8.5), with a significant difference between countries (between 9-12% in Burkina Faso and Nigeria; between 3-6% in Ghana; and <3% in Côte d'Ivoire, Mali and Senegal). 1 When considering previous studies on HCV prevalence among patients in the two participating countries, the HCV prevalence ranged between 1.1-3.3% in Côte d'Ivoire and between 2.4% and 10.0% in Burkina Faso. [23] [24] [25] [26] [27] The variation of risk factors for HCV infection (e.g., scarification or medical practice…) according to geographical region, even inside a country, population studied, year of study and diagnostic assay used might explain the difference of HCV prevalence.
Our results were in accordance with the study conducted in Guinea Bissau. In this study, there was no statistical difference of the prevalence of HCV according to HIV types. 15 Thus, the specificity of HIV-2 infection seems to have no impact on the transmission and the rate of HCV infection. However, we found that all (100%) HIV-1 and HIV-1&2 dually reactive patients with HCV infection had detectable viral load versus only 43.8% of HIV-2 infected patients. This interesting result needs to be further explored.
For HCV screening, it is suggested that nucleic acid testing (NAT) for HCV RNA be performed directly following an HCV positive test result to establish a definitive diagnosis of HCV infection in addition to the use of NAT as part of the evaluation for treatment eligibility. 28 The proportion of anti-HCV positive participants with a significant HCV replication is consistent with previous studies from West Africa. 15, [25] [26] [27] In a recent meta-analysis conducted among HIV-positive individuals in SSA, the pooled proportion of positive serology samples that were positive for HCV RNA was 54.0% for patients from West Africa, with a variation ranging from 7.7% to 94.7%. 1 Our study confirms the high prevalence of HCV infection in West Africa. However, most of the people with HCV infection in this region have very limited access to HCV testing and thus remain undiagnosed until they have clinical symptoms of cirrhosis or HCC. 29 To date, it is recommended that HCV serology testing be offered to individuals who are part of a population with high HCV prevalence or who have a history of HCV risk exposure and/or behavior. 28 Facing the high prevalence of HCV infection among HIV-infected reported here in line with previous reports from West Africa in both HIV-infected and uninfected people HCV testing might be recommended for the general population. [25] [26] [27] Approaches for large-scale HCV testing earlier in the course of disease should be identified.
Today with the availability of directacting antiviral agents (DAA), very effective and much less toxic, HCV infection can be cured or even eliminated. 13 Thus, all efforts, including the availability of screening tests and NAT for HCV RNA, information and training on HCV prevention and care of general practitioners and other health care workers, must be implemented for the control or elimination of this disease. Our study has some limitations. Data on certain risks of HCV infection, such as body mutilations and drug use, were not collected and genotype test was not performed. In West Africa, genotypes 2 and 1 are predominant. 24, [30] [31] [32] The representativeness of our HIV-infected population might be limited as included patients were recruited in selected HIV clinics disregarding patients not in care. [25] [26] [27] Therefore, a population-based survey, involving all subgroups of HIV-infected patients, could provide a more accurate estimate of the HCV prevalence in each country. Despite these limitations, this study has also major strengths. It took place in two different West African countries and included a large sample of HIV-infected patients. In addition, HCV RNA was performed, giving therefore the proportion of chronic HCV infection.
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Conclusions
HCV infection is high in West African HIV-infected patients, irrespective of HIV type. Therefore, screening should be systematically performed in HIV-positive patients to allow a better management of this co-infection. Also, since HCV is now curable with the DAA, strategies that will lead to a large-scale diagnosis and care of this disease earlier in the course of the disease are needed. 
Ethics approval and consent to participate
Availability of data and materials
All of data used are available and could be requested from the authors.
